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ABSTRACT 19 
Human trials of formaldehyde-inactivated RSV (FI-RSV) vaccine in 1966-67 caused 20 
disastrous worsening of disease and death in infants during subsequent natural RSV 21 
infection. The reasons behind vaccine-induced augmentation are only partially 22 
understood, and fear of augmentation continues to hold back vaccine development. 23 
We now show that mice vaccinated with FI-RSV show enhanced local recruitment of 24 
conventional CD4+ T cells accompanied by a profound loss of regulatory T cells 25 
(Tregs) in the airways. This loss of Tregs was so complete that additional depletion 26 
of Tregs (in transgenic DEREG mice) produced no additional disease enhancement. 27 
Transfer of conventional CD4+ T cells from FI-RSV vaccinated mice into naïve RSV 28 
infected recipients also caused a reduction in airway Treg responses, and boosting 29 
Tregs with IL-2 immune complexes failed to restore normal levels of Tregs or to 30 
ameliorate disease. However, delivery of CCL17/22 via the airway selectively 31 
recruited airway Tregs and attenuated vaccine-augmented disease, reducing weight 32 
loss and inhibiting local recruitment of pathogenic CD4+ T cells. These findings 33 
reveal a novel and unexpected mechanism of vaccine-induced disease 34 
augmentation, and indicate that selective chemoattraction of Tregs into diseased 35 
sites may offer a novel approach to the modulation of tissue-specific inflammation.36 
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Introduction 37 
Respiratory syncytial virus (RSV) causes common colds in adults but is the major 38 
cause of infantile bronchiolitis (1), characterized by an intense local inflammatory 39 
response to infection. RSV is estimated to cause 34 million cases of lung infection 40 
annually, some 3.4 million hospitalizations and the deaths approximately 199 000 41 
children under 5 years of age worldwide (2). Between 25 and 40% of previously 42 
healthy RSV infected infants develop signs of lower respiratory tract infection which 43 
may develop into viral bronchitis, bronchiolitis or pneumonia (2). Those recovering 44 
from severe disease are at high risk of recurrent wheeze in later childhood and RSV 45 
is increasingly recognized as an important cause of winter deaths in the elderly. 46 
Despite this enormous disease burden, there is still no vaccine for human use. 47 
Trials of formaldehyde-inactivated RSV (FI-RSV) vaccine in 1966-67 caused 48 
disastrous worsening of disease and deaths in infants during subsequent natural 49 
RSV infection (3). The mechanisms that cause disease augmentation are 50 
incompletely understood, but include aberrant Th2-mediated disease triggered by 51 
generation of carbonyl groups (4), defective Toll-like receptor signalling (5) and 52 
induction of poorly neutralising antibody (6). Although it is clear that CD4 T cells play 53 
a major pathogenic role, little is known how these responses are regulated. 54 
CD4+CD25hiforkhead box p3 (Foxp3)+ regulatory T cells (Treg) play a crucial role in 55 
controlling immune responses. Human genetic Treg defects causes multi-organ 56 
inflammatory disease (7, 8), and depletion of Treg in mice can lead to an analogous 57 
inflammatory syndrome mainly affecting the gut and skin (9, 10). Tregs are widely 58 
distributed in lymphoid and non-lymphoid sites and express a variety of 59 
chemoattractant receptors and adhesion molecules that determine their migration in 60 
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and out of tissue compartments (11). Amongst the various homing and migration 61 
receptors CCR4/8 expression on human Tregs seems particularly important (12), 62 
suggesting that the ligands CCL1, CCL17 and CCL22 may guide the migration of 63 
Tregs to specific areas and thus suppress local inflammation (13-15). Most 64 
remarkably, mice lacking CCR4 expression on Tregs develop lymphocytic infiltration 65 
and severe inflammatory disease of the skin and lungs (16), and CCL22-directed 66 
Treg recruitment has been used to prevent murine autoimmune diabetes (17). 67 
We now show that mice vaccinated with FI-RSV exhibit an almost complete absence 68 
of Tregs in the airways during RSV infection. Moreover, selective recruitment of 69 
Tregs by chemokine administration of CCL17/22 re-established a local airway Treg 70 
population, so attenuating the pathogenic effects of vaccine-induced CD4 T cells. 71 
The use of appropriate chemokines to draw regulatory cells into inflamed tissues 72 
offers a novel approach to the treatment of inflammatory disorders. 73 
 74 
Results  75 
FI-RSV vaccination attenuates airway Treg responses to RSV infection 76 
Mice vaccinated with formalin inactivated RSV (FI-RSV) showed augmented disease 77 
and weight loss after RSV infection (Fig. 1A). This was accompanied by elevated 78 
total cell numbers on day 4 post RSV infection in BAL and lung (Fig. 1B). Flow 79 
cytometric analysis of the BAL cells showed a significant increase of CD4 T cells 80 
(CD3+CD4+Foxp3-) but a remarkable loss (both frequency and numbers) of Tregs in 81 
FI-RSV vaccinated mice, compared to unvaccinated control mice infected with RSV. 82 
The loss of Tregs in FI-RSV vaccinated mice was evident as early as day 2, but was 83 
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virtually complete by day 4 (Fig. 1D and E). RSV infected mice vaccinated with 84 
formalin treated mock infected Hep-2 cell material (FI-Mock) showed a significant but 85 
less pronounced increase of CD4 T cells and a slight drop in Treg frequencies on 86 
day 4 post infection compared to unvaccinated controls (Fig. 1C-E); such effects 87 
have previously been noted, and ascribed to anti-cell responses since both the virus 88 
and the vaccine stocks were grown on Hep-2 cells (18). However, the ratio of Tregs 89 
to CD4 T cells was most markedly reduced in the airways of FI-RSV vaccinated mice 90 
(Fig. 1 F). Uninfected mice showed no cell efflux into the airways, regardless of 91 
vaccination with FI-RSV or FI-Mock. The effects were most obvious in the BAL cells, 92 
but similar changes in Treg proportions and numbers were detected in the lung cells 93 
(Fig.S1 A and B). However, there was no significant loss of Tregs in local draining 94 
lymph nodes (Fig.S1 C), indicating that the effect is tissue-specific and confined to 95 
the site of infection. 96 
Since disease enhancement was associated with reduced numbers of Treg cells, we 97 
attempted to reduce disease severity by administration of immune complexes of IL-98 
2/anti-IL-2 (IL-2 Cx) prior to RSV infection. This procedure has been shown to 99 
selectively activate and expand Tregs without significantly affecting conventional 100 
effector CD4 T cells (19, 20), causing active suppression of immune activation and 101 
disease in vitro and in vivo and reducing lung inflammation in RSV disease (20). 102 
These IL-2 immune complexes increased the proportion of Tregs in the airways at 103 
day 2 of FI-RSV vaccinated, RSV infected mice (e.g. Fig. S1D and E cf. 1 D), but the 104 
benefits were only transient and Tregs showed a marked decline by day 4 (Fig. S1 D 105 
and E). Despite this treatment, the proportion of disease-associated conventional 106 
CD4 T cells increased during this period, just as it did in mice without IL-2 Cx 107 
injections (e.g. Figs. S1E cf. 1 C). 108 
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Although it was previously demonstrated that Tregs can be starved of IL-2 produced 109 
by effector T cells during acute infection (21) our results suggest that IL-2 withdrawal 110 
is not the cause of the observed ‘crash’ in Tregs. 111 
 112 
Selective Treg depletion does not lead to additional enhancement of disease  113 
Bacterial artificial chromosome-transgenic "depletion of regulatory T cell" (DEREG) 114 
mice express diphtheria toxin (DT) receptor and enhanced green fluorescent fusion 115 
protein under the control of the foxp3 gene locus, allowing selective depletion of 116 
Foxp3+ Treg cells by DT injection (22). Non-depleted FI-RSV vaccinated DEREG 117 
mice respond to RSV infection similarly to WT mice. We have shown that two 118 
consecutive injections of DT into DEREG mice causes virtually complete Treg 119 
depletion, resulting in considerable disease enhancement after RSV infection (20). 120 
However, depletion of Tregs from FI-RSV vaccinated, RSV infected DEREG mice 121 
did not produce any additional enhancement of disease (Fig.S2 A, B and C) and 122 
failed to increase the numbers or CD4 T cells in the lung or BAL on day 2 or 4 post 123 
RSV infection (Fig. S2B and C). Thus, the functional deficit of Tregs caused by FI-124 
RSV vaccination is effectively complete, since depletion of Tregs had no significant 125 
additional effect. 126 
 127 
Vaccine-primed CD4 T cells attenuate airway Treg responses 128 
To determine the role of CD4 T cells in causing the loss of airway Tregs after RSV 129 
infection of primed mice, naive mice were injected i.v. with purified CD4 T cells from 130 
spleen and mesenteric lymph nodes derived from either FI-RSV vaccinated or naïve 131 
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mice. Mice that received CD4 T cells from FI-RSV vaccinated mice displayed 132 
enhanced weight loss and increased cellular influx into the airways on day 4 post 133 
RSV infection (Fig. 2 A and B). Flow cytometric analysis of the BAL showed a 134 
significant increase of CD4 T cells but a remarkable loss of Treg frequencies on day 135 
4 post infection in RSV infected mice which received CD4 T cells from FI-RSV 136 
vaccinated mice compared to controls (Fig. 2 C and D). This also led to a significant 137 
decrease of the Treg/CD4 T cells ratio (Fig. 2E). Adoptive transfer of naive CD4 T 138 
cells also led to increased cellular influx into the airways on day 4 post infection 139 
(Fig.2 B and D; probably due to large numbers of partially activated CD4 T cells 140 
reaching the lungs after i.v. injection), but these effects were significantly less 141 
marked than those of CD4 cells from FI-RSV vaccinated mice. Therefore, primed 142 
and activated CD4 T cells (especially those induced by FI-RSV vaccination) are 143 
responsible for the attenuation of airway Treg responses after RSV challenge. 144 
 145 
CCR4 expression by Tregs and chemokine levels in the airways. 146 
To further examine the causes of Treg deficiency in the airways of mice with 147 
augmented disease, we studied chemokine receptor expression and chemokine 148 
production by the infected airways. CCR4 plays a pivotal role in Treg migration in 149 
both man and mouse (15, 16, 23), and expression of CCR4 on Tregs is required for 150 
appropriate migration to the skin or respiratory tract. Mice lacking CCR4 on Tregs 151 
develop lymphocytic infiltration and inflammation of the lung and skin with local influx 152 
of CD4 T cells and granulocytes (16). This pattern of pathology is reminiscent of the 153 
inflammation seen in the lungs of FI-RSV vaccinated children or mice infected with 154 
RSV (24).  155 
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We therefore analysed the expression of CCR4 on airway Tregs. After RSV 156 
infection, airway Tregs of all experimental groups showed greater expression of 157 
CCR4 than conventional CD4 T cells, either by flow cytometry (Fig. S3A and B) or by 158 
quantitative PCR analysis of gene expression on sorted cells from BAL (Fig. S3C). or 159 
from lung (Fig. S3D). Therefore, the observed defect in Treg recruitment cannot be 160 
explained by reduced chemokine receptor expression on Tregs. 161 
Since CCR4 is present and expressed on Tregs regardless of priming, we 162 
investigated the possibility that a lack of CCR4’s specific chemokines (CCL17/22) 163 
might explain the reduced Treg recruitment in vaccinated RSV infected mice. We 164 
attempted to measure levels of CCL17 and CCL22 in the airway fluid in the different 165 
groups (Fig S3E). In most of the groups CCL17 was under the detection limit. 166 
However airway fluid from IL-2 Cx injected mice contained higher levels of CCL17 167 
and CCL22 on day 2 post infection. Levels of both these chemokines decreased by 168 
day 4 post infection at the time of declining Treg numbers, compatible with the 169 
possibility that the increased Treg frequencies in the airways of IL-2 Cx treated mice 170 
on day 2 post infection were due to CCL17/22-mediated chemoattraction of Treg 171 
trafficking into the inflamed airways (16). There was no significant difference in levels 172 
of CCL22 between the other groups (Fig S3E). These findings suggest that 173 
CCL17/22 may play a role in attracting Treg to the airway and modulating disease, 174 
but that our methods of detecting these chemokines may not be sufficiently sensitive 175 
to fully elucidate their role.  176 
Administration of CCL17/22 via the airways re-establishes Treg population 177 
Since Tregs displayed CCR4 and we were unable to show whether there was a 178 
defect in chemokine production, we next tested the effect of delivering CCL17/22 via 179 
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the airway. Since topical vaginal application of CXCL9/10 recruits herpes virus-180 
specific tissue-resident primed memory T cells to the genital mucosa (25), we 181 
reasoned that delivering CCL17/22 via the airway might recruit Tregs and thus 182 
reduce disease severity. We gave a single intranasal dose of CCL17/22 on day 2 183 
after RSV challenge, and found that this greatly reduced weight loss up to day 8 post 184 
infection (Fig. 3A), while increasing Treg recruitment into the BAL (Fig 3 B and C). 185 
This was accompanied by a marked reduction in conventional CD4 T cells compared 186 
to PBS control mice (Fig.3B and C). Administration of either CCL17 or CCL22 alone 187 
was much less effective (Fig.S4A), suggesting that these 2 chemokines act 188 
synergistically. CCL17/22 administration also reduced the proportion of CD4 T cells 189 
that produced IFN-γ and/or TNF-α (Fig. 3D and Fig. S4B) and significantly increased 190 
the ratio of Tregs to CD4 T cells (Fig. 3E) but did not affect total cell numbers in the 191 
lung or BAL or the recruitment of granulocytes to the airway (Fig. S4C). We could not 192 
detect IL-17 or IL-4 producing CD4 T cells in the lung or airways at any time by flow 193 
cytometry, suggesting that Tregs predominantly modulate Th1, rather than the Th2 194 
or Th17 CD4 T cell subsets in this situation. Although the Treg recruitment to the 195 
airways in FI-RSV vaccinated mice was inhibited for at least 8 days post infection the 196 
increase of Tregs in the airways after chemokine treatment was sustained at least 197 
until day 8 post infection (Fig. S5A to C). Notably, the weight loss recovery already 198 
started by day 5 post RSV infection, as soon as the number of FI-RSV specific CD4 199 
T cells declined. There was no significant difference between levels or total numbers 200 
of CD4 T cells between CCL17/22 treated and untreated mice on day 8 post 201 
infection (Fig. S5B and C). However, CCL17/22 administration did not affect mice 202 
undergoing primary RSV infection, in which case the balance of regulatory and 203 
disease-causing cells is already under appropriate control. These results show 204 
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clearly that selective chemoattraction of Tregs to the airway by administration of 205 
CCL17/22 reduces the recruitment and activity of conventional CD4 T cells and 206 
reverses the enhanced lung inflammation resulting from vaccination with FI-RSV. 207 
We next examined whether neutralization of CCL17/ 22, by i.p. injection of anti-208 
chemokine antibodies on day 1 post RSV infection (with or without chemokine 209 
instillation on day 2 post infection), was able to prevent Treg recruitment into the 210 
airways and the consequent effects (Fig. S6). Anti-CCL17/ 22 (but not goat IgG 211 
isotype control) prevented the effects of CCL17/22 treatment, reducing Treg and 212 
increasing CD4 T cell frequencies on day 4 post infection. Importantly, anti-213 
CCL17/22 treatment further decreased Treg frequencies in the airways in vaccinated 214 
mice compared to vaccinated control mice, emphasizing the important role of 215 
CCL17/22 in Treg recruitment even under these conditions.  216 
In order to demonstrate that additional recruited Tregs in the airways of FI-RSV 217 
vaccinated mice treated with CCL17/22 are directly responsible for the decrease in 218 
CD4 T cells after RSV infection, FI-RSV vaccinated BALB/c DEREG mice were 219 
depleted of Tregs by injections of DT and infected with RSV. Treg depleted, FI-RSV 220 
vaccinated DEREG or untreated and non-depleted vaccinated BALB/c mice, 221 
CCL17/22 treated or untreated mice served as controls. We found that only non-222 
depleted mice given CCL17/22 showed significant reduced weight loss after RSV 223 
infection accompanied by increased Treg recruitment and by a marked reduction in 224 
CD4 T cells and Treg/CD4 T cells ratio in the BAL (Fig.4A, B and C). Therefore, Treg 225 
recruitment is necessary for the beneficial effects of administration of CCL17/22 via 226 
the airway.  227 
  228 
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Discussion 229 
Studying vaccine-augmented disease, our results show that RSV infected mice 230 
suffering the effects of exuberant RSV-specific CD4 T cell memory responses show 231 
a marked reduction in airway Treg cells, with a virtually complete loss of immune 232 
regulatory function. The ‘crash’ in Tregs can be partially reproduced by adoptive 233 
transfer of activated CD4 T cells. Most remarkably, selective recruitment of disease-234 
attenuating Tregs by the administration of CCL17/22 into the airways rapidly restored 235 
local immunoregulation and caused a sustained reduction in disease severity, even if 236 
the chemokines were delivered after virus-induced inflammation was at its peak. 237 
Together, these results show that Tregs play a key role in determining the balance 238 
between the beneficial and disease-enhancing components of cellular immunity.  239 
Consideration of the site at which different components of the immune response act, 240 
is essential in understanding this complex but informative disease model. It is known 241 
that generalized depletion of Tregs (either with anti-CD25 antibody or in genetically 242 
modified mice) enhances RSV-induced disease and increases T cell activation at 243 
multiple sites (20, 26-28). We now show that an almost complete Iocal depletion of 244 
Tregs occurs in the airways of vaccine-sensitised RSV infected mice, and that this 245 
crash in local Tregs allows the effect of disease-causing T cells to become dominant. 246 
Whereas Treg depletion during primary RSV infection causes disease enhancement, 247 
depletion of Tregs in FI-RSV vaccinated DEREG mice caused no further disease 248 
enhancement during RSV infection. Thus, the functional deficit of Tregs in the 249 
airways was virtually complete under these conditions and additional depletion of 250 
Tregs had no significant additional effect. The disappearance of Tregs, which was 251 
most evident in the airways, was seen also in the lung but not in the spleen or 252 
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draining nodes. The loss of Tregs in FI-RSV vaccinated mice was evident as early as 253 
day 2, but was virtually complete by day 4 continued to at least day 8 after RSV 254 
infection. Thus, attenuation of Treg responses is focussed at the site of enhanced 255 
disease.  256 
To explain our observations, we suggest that primed conventional CD4 T cells cause 257 
a loss of chemoattraction of Tregs (29), probably by an action on the cells that make 258 
CCL17 (e.g. airway epithelial cells and DCs) and CCL22 (DCs and macrophages; 259 
illustrated diagrammatically in Fig. S7). This explanation is supported by our finding 260 
that passive transfer of CD4 T cells from vaccinated mice led to reduced Treg 261 
recruitment, and is compatible with the known effects of CD4 T cells on innate 262 
immune responses (30). Although T cell subsets that do not express Foxp3 can have 263 
suppressive functions (31) and might play an important role in controlling lung 264 
inflammation, our studies indicate that variations in FoxP3+ cells rather than 265 
additional regulatory subsets sufficiently explain the observed changes in disease in 266 
FI-RSV vaccinated mice. However, it is clearly important to investigate the role of 267 
additional suppressive mechanism in future studies.  268 
Recent studies suggested an important role for CCR4 in human and mouse Treg 269 
migration (15, 16, 23). Notably, Sather et al showed that CCR4 expression on Tregs 270 
is required for appropriate migration to the skin or respiratory tract, and that mice 271 
lacking CCR4 on Tregs develop lymphocytic infiltration and inflammation of the lung 272 
and skin with local influx of CD4 T cells and granulocytes (16). This chronic and 273 
progressive disease bears close similarity to the acute inflammatory disease that we 274 
observe in FI-RSV vaccinated mice after infection with RSV (24). However, we found 275 
that FI-RSV vaccinated mice had similar levels of CCR4 expression on lung and 276 
airway Tregs to those seen in mice undergoing primary infection with RSV, in which 277 
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no crash in Tregs occurs. Thus, we do not believe that downregulation of CCR4 on 278 
Tregs is responsible for their failure to accumulate in enhanced disease.  279 
Since we could not detect CCL17 in the BAL or lung homogenates and found only 280 
low levels of CCL22 in the lungs, we were unable to show directly whether a lack 281 
chemoattraction was responsible for the crash or Tregs. However, soluble mediators 282 
can be difficult to detect, especially if they are rapidly taken up, destroyed or bound 283 
to cells. It has recently been found that adenovirus recombinant expression of 284 
CCL22 in pancreatic islets recruits Tregs and causes long-term protection from 285 
autoimmune diabetes in NOD mice (17) and that local administration of chemokines 286 
can ‘pull’ activated virus-specific cells into the vaginal mucosa (25). In order to test a 287 
similar approach we administered the chemokines CCL17/ 22 via the airway in the 288 
hope of attracting Tregs into the site of infection and attenuating disease. A single 289 
dose of this chemokine cocktail was indeed effective, even if administered on day 2 290 
after RSV challenge (a time at which enhanced disease is already well established in 291 
FI-RSV vaccinated mice), showing that administration of additional CCL17/22 via the 292 
airway can re-establish a local Treg population and attenuate vaccine-enhanced 293 
disease.  294 
The implication of these findings is that selective recruitment of Tregs by appropriate 295 
chemokine administration might rapidly reduce the severity of inflammation and 296 
disease, even when inflammation is well established, offering a novel therapeutic 297 
avenue in the treatment of tissue-specific inflammation. Although the lung is unique 298 
in allowing chemokine delivery via the airway, it is possible that disease at other sites 299 
(e.g. the skin, joints and vagina) might also respond favourably to the local 300 
administration of chemokines that selectively recruit regulatory T cells to the site of 301 
inflammation.  302 
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MATERIAL AND METHODS 303 
Mice, virus stocks and infection and FI-RSV vaccination 304 
Plaque-purified human RSV (type A2 strain, ATCC) was grown in HEp-2 cells. 305 
Formalin-inactivated RSV vaccine (FI-RSV) was prepared as described before (4). In 306 
brief, RSV was grown in HEp-2 cells, flasks were frozen and thawed, cells harvested 307 
and pooled. The cell suspension was sonicated for 3 min on ice and spun at 1,000 g 308 
for 10 min at 4 °C. A 40 % formalin solution was added to the supernatant to give a 309 
final concentration of 1:4000 (2.5 μl of formalin per each 4 ml of virus stock) and 310 
incubated for 72 h at 37 °C, 5 % CO2. After, the supernatant was centrifuged at 311 
50,000 g for 1h at 4 °C and the pellet diluted (1:25 of the starting volume) in serum-312 
free medium. Aluminium Hydroxide (12 μl per 1 ml of supernatant) was added and 313 
the suspension shaken for 30 min at RT before centrifugation at 1,000 g for 30 min. 314 
The final pellet was resuspended 1:4 in PBS (i.e. 1:100 of the starting volume) and 315 
stored frozen at -80°C. 316 
Six to ten week old BALB/c mice (Harlan, UK) or DEREG mice (22) on BALB/c 317 
background were maintained in pathogen-free conditions under UK Home Office 318 
guidelines. Age- and sex-matched mice were lightly anesthetized and infected 319 
intranasally (i.n.) with 106 focus-forming units (FFU) RSV in 100 µl. For FI-RSV 320 
vaccination, BALB/c mice were injected intramuscularly (i.m.) with 50 μl FI-RSV (3 321 
mg/ml protein). Three weeks later mice were infected with RSV as described above. 322 
IL-2 Complex injections 323 
IL-2 complexes (IL-2 Cx) were obtained as described (19) by mixing 1 μg rmIL-2 324 
(Peprotech) and 5 μg anti-IL-2 (Clone JES6-1A12; eBioscience) and incubating at 37 325 
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˚C for 30 min. Age- and sex-matched BALB/c mice received daily i.p. injections of IL-326 
2 Cx or PBS for three consecutive days (-3,-2 and -1) before RSV infection (20). 327 
Diphtheria toxin injections 328 
DEREG mice (22) were injected with 0.75 µg of DT (Merck) in PBS i.p. on days -2 329 
and -1, days 2 and 5 after RSV infection to induce and maintain Foxp3+ T cell 330 
depletion as previously described (20). 331 
Chemokine and antibody administration 332 
Chemokine administration was performed by intranasal instillation of 500 ng of 333 
CCL17 and 22 (R&D Systems) in 100 µl PBS under light anaesthesia, ensuring deep 334 
lung inhalation on day 2 post infection. For neutralization of CCL17 and 22, mice 335 
were injected with one dose i.p. of 20 µg of anti CCL17 and anti-CCL22 or IgG 336 
isotype control (goat anti- mouse antibodies, R&D Systems) in 200 µl PBS on day 1 337 
post RSV infection.  338 
Adoptive cell transfer 339 
BALB/c mice were injected intramuscularly (i.m.) with 50 μl FI-RSV. Three weeks 340 
later isolation of CD4 T cells from spleen and mesenteric lymph nodes was 341 
performed using a negative CD4 T cell isolation kit II (Miltenyi) and the Auto MACS 342 
pro (Miltenyi). Purity was confirmed by flow cytometry and was ≥ 90 %. Purified CD4 343 
T cells (27x106/mouse) were transferred intravenously into naïve recipients. These 344 
mice were infected with RSV i.n. 3 days later. 345 
Real-time PCR 346 
Lung and BAL CD4 T cells (CD4+GFP-) and Tregs (CD4+GFP+) from FI-RSV 347 
vaccinated and RSV infected DEREG mice were sorted on a FACS Aria II (BD). 348 
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Total RNA was isolated from purified T cells using the Qiagen RNeasy Micro Kit with 349 
on-column DNase digestion using the RNase-Free DNase set (according to the 350 
manufacturer’s protocol). cDNA was generated using the Superscript III FirstStrand 351 
Synthesis SuperMix for RT-PCR and oligodT primers (Invitrogen), according to the 352 
manufacturer’s protocol. cDNA was used as a template for quantitative real-time 353 
PCR using TaqMan Gene Expression Assay (Applied Biosystems) for mouse CCR4. 354 
PCR and analysis was performed using a 7500 Fast Realtime PCR System (Applied 355 
Biosystems). Gene expression was calculated relative to GAPDH by the formular 356 
1/2∆∆CT. 357 
Cell collection and preparation 358 
Bronchoalevolar lavage (BAL) was carried out using 1 ml PBS containing 12 mM 359 
lidocaine flushing the lungs 3 times. In order to obtain a single cell suspension, LNs 360 
were mashed through a cell strainer and lungs were processed with the gentleMax 361 
dissociator (Miltenyi Biotech) according to the manufacturer’s protocol using 362 
Collagenase D (50 μg/ml, Sigma). Total cell counts were determined by flow 363 
cytometry using Count Bright counting beads (Invitrogen) and dead cells were 364 
excluded by staining for 7-amino-actinomycin D (7-AAD, Sigma). For determination 365 
of cellular composition in the BAL, cells were transferred onto a microscope slides 366 
(Cytospin, Thermo Scientific, UK) and stained with hematoxylin and eosin (H&E) 367 
(Reagena, Gamidor, UK). 368 
Flow cytometry 369 
For flow analysis the LIVE/DEAD Fixable Red Dead cell stain kit (Invitrogen) was 370 
used to exclude dead cells. Cells were incubated with FcγIII/II receptor antibody (BD 371 
Biosciences) diluted in PBS containing 1% BSA and 5 mM EDTA and were 372 
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subsequently labelled with the following antibodies (from BD Biosciences unless 373 
otherwise stated): PE-Cy7 or V500 conjugated anti-CD3 (145-2C11), Pacific Blue 374 
conjugated anti-CD4 (RM4-5), PE conjugated anti-CCR4 (2G12; Biolegend). For 375 
intracellular staining for Foxp3, the Foxp3 staining kit (eBioscience) using APC or 376 
FITC conjugated anti-Foxp3 (FJK-16s;eBioscience) was used following 377 
manufacturer’s recommendations. In order to detect intracellular IFN-γ production, 378 
cells were stimulated with 100 ng/ml PMA and 1 μg/ml Ionomycin in complete RPMI. 379 
After 1 h incubation monensin (Golgi Stop, BD) was added. Following 2 additional 380 
hours of incubation, cell surface staining was followed by intracellular staining with 381 
Percp Cy 5.5 anti-IFN-γ (XMG1), PE anti-TNF-α (MP6-XT22), APC anti-IL-4 (11B1) 382 
or Alexa 700 anti-IL-17 (TC11-18H1) using the Foxp3 staining kit (eBioscience). 383 
Cells were acquired on a LSR II (BD, United Kingdom) with data analyzed using 384 
Flow Jo software. Cells were gated for live cells, singlets and lymphocytes before 385 
analysis of indicated markers. 386 
Chemokine detection 387 
CCL17 and CCL22 levels in the BAL were measured by ELISA following 388 
manufacturer’s recommendations (R&D). The concentration of cytokines in each 389 
sample was determined according to the standard curve. The detection limit for 390 
CCL17 was 31.2 pg/ml and for CCL22 7.8 pg/ml. 391 
Statistical analysis 392 
Results are presented as means ± SEM. The significance of results between the 393 
groups was analyzed by two-tailed, unpaired Student’s t test (*p< 0.05, **p < 0.01, 394 
***p< 0.001) (Prism software; Graph-Pad Software Inc.). p values of <0.05 were 395 
considered significant.*p < 0.05, **p < 0.01, ***p < 0.001 was used to compare 396 
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different groups on one time point and #p < 0.05, ##p < 0.01, ###p < 0.001 was used 397 
for comparing one experimental group at different time points.  398 
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Figure Legends 518 
Figure 1. FI-RSV vaccination attenuates BAL Treg responses during RSV 519 
infection. 520 
521 
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Naive, FI-RSV or FI-Mock vaccinated mice were infected intranasally with RSV (day 522 
0). (A) Illness was monitored daily by weight for 4 days after RSV infection. On day 523 
4, BAL fluid was obtained and cells extracted from the disrupted lungs. (B) Total 524 
numbers of cells in the BAL and lung were enumerated on day 2 and 4. (C) 525 
Frequencies of Foxp3– gated CD3+CD4+ T cells (CD4 T cells) and (D) CD3+CD4+ 526 
gated Foxp3+ T cells (Tregs) were quantified using flow cytometry on day 2 and 4 527 
post RSV infection. (E) Total cell numbers of CD4 T cells and Tregs on day 2 and 4 528 
post RSV infection. (F) Ratio of total number of Tregs to total number of CD4 T cells 529 
in the BAL on day 2 and 4 post RSV infection. Graphs show data from one of two 530 
independent experiments with 5 mice per group. Results are presented as means ± 531 
SEM. The significance of results between the groups was analyzed by two-tailed, 532 
unpaired Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001 was used to compare 533 
different groups on one daypoint, and #p < 0.05, ##p < 0.01, ###p < 0.001 for 534 
comparing one group at different daypoints. 535 
  536 
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Figure 2. Transferred CD4 T cells attenuate airway Treg responses. 537 
538 
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CD4 T cells from naïve or FI-RSV vaccinated mice were transferred intravenously 539 
into naïve recipients on day -3, with RSV infection on day 0 and BAL harvest on day 540 
4. (A) Illness was monitored daily by weight, displayed as percentage of original 541 
weight. (B) Total numbers of BAL cells. (C) Frequencies of Foxp3– gated CD3+CD4+ 542 
T cells (CD4 T cells) and Tregs quantified using flow cytometer.(D) Total calculated 543 
numbers of CD4 T cells and Tregs. (E) Ratio of Tregs to CD4 T cells. One 544 
representative study of two independent experiments with 5 mice per group is 545 
shown, presented as means ± SEM. The significance of results between the groups 546 
was analyzed by two-tailed, unpaired Student’s t test. *p < 0.05, **p < 0.01, ***p < 547 
0.001. 548 
  549 
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Figure 3. Effects of chemoattraction of Tregs by CCL17/22 administration via 550 
the airway. 551 
 552 
BALB/c mice were vaccinated with FI-RSV and infected three weeks later with RSV 553 
i.n. (day 0). Mice were given a mixture of 0.5 µg CCL17 and 0.5 µg of CCL22, or 554 
PBS intranasally on day 2, and BAL cells were harvested from 5 mice per group on 555 
day 4 and weight monitored to day 8 in the remainder. (A) Daily weight after RSV 556 
infection as percentage of original weight. (B) Frequencies of Tregs and Foxp3- 557 
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gated CD4 T cells by flow cytometry in mice with (17/22) or without (‘nil’) intranasal 558 
CCL17/22. (C) Frequencies (left) and total numbers (right) of Tregs and CD4 T cells. 559 
(D) Frequencies of CD4+IFN-γ+ T cells, CD4+TNF-α+ T cells and CD4+TNF-α+IFN-γ+ 560 
T cells in the BAL on day 4 post vaccination and RSV infection. (E) Ratio of total 561 
number of Tregs to total number of CD4 T cells in the BAL on day 4 post RSV 562 
infection. One representative study of two independent experiments with 5 mice per 563 
group is shown. Results are presented as means ± SEM. The significance of results 564 
between the groups was analyzed by two-tailed, unpaired Student’s t test. *p < 0.05, 565 
**p < 0.01, ***p < 0.001. 566 
  567 
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Figure 4. Recruited Tregs are necessary to control CD4 T cells response in the 568 
airways. 569 
 570 
BALB/c WT or DEREG mice or were vaccinated with FI-RSV and infected three 571 
weeks later with RSV i.n. (day 0). When indicated, mice were treated i.n. with a 572 
mixture of 0.5 µg both CCL17 and 22, or PBS on day 2 post RSV infection or/ and 573 
depleted of Tregs by diphtheria toxin injections on day -2,-1 and 2. All mice were 574 
sacrificed on day 4 and BAL cells obtained. (A) Daily weights as percentage of 575 
original weight. (B) Frequencies of CD4 T cells and Tregs by flow cytometry. (C) 576 
Ratio of numbers of Tregs to CD4 T cells. One representative study of two 577 
independent experiments with 5 mice per group is shown. Results are presented as 578 
means ± SEM. The significance of results between the groups was analyzed by two-579 
tailed, unpaired Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.  580 
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Supplemental Figure Legends 581 
31 
 
Supplemental Figure S1. FI-RSV vaccination leads to a reduction of Tregs in 582 
the lung but not in the draining LN after RSV infection. 583 
 584 
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FI-RSV or FI-Mock vaccinated mice were infected with RSV on day 0. Lungs were 585 
harvested on day 2 and day 4 post infection. (A) Quantification of frequencies of 586 
Tregs and Foxp3– gated CD3+CD4+ T cells (CD4 T cells) in the lung on day 2 and 4 587 
post RSV infection. (B) Total cell numbers of Tregs and CD4 T cells in the lung on 588 
day 2 and 4 post RSV infection. (C) Frequencies of Tregs and CD4+ T cells in the 589 
mediastinal LNs on day 2 and 4 post RSV infection. (D) Frequencies of 590 
CD3+CD4+gated Tregs in the BAL of FI-RSV vaccinated, IL-2 Cx injected mice on 591 
day 2 and 4 post RSV infection. (E) Quantification of frequencies of Tregs and CD4 592 
T cells on day 2 and 4 post RSV infection in FI-RSV vaccinated, IL-2 Cx injected 593 
mice. One representative study of two independent experiments with 5 mice per 594 
group is shown. Results are presented as means ± SEM. The significance of results 595 
between the groups was analyzed by two-tailed, unpaired Student’s t test. *p < 0.05, 596 
**p < 0.01, ***p < 0.001 was used to compare different groups on one daypoint and 597 
#p < 0.05, ##p < 0.01, ###p < 0.001 was used for comparing one group at different 598 
daypoints. *p<0.05, **p<0.01, ***p<0.001. 599 
  600 
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Supplemental Figure S2. Depletion of Foxp3+ cells in FI-RSV vaccinated 601 
DEREG mice does not increase weight loss or cellular influx into the lungs 602 
after RSV infection. 603 
  604 
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(A) Illness was monitored daily by weight for 8 days after RSV infection, displayed as 605 
percentage of original weight. (B) Total numbers of cells in the lung (top panel) and 606 
BAL (bottom panel) was enumerated on day 2 and 4 from RSV infected FI-RSV 607 
vaccinated mice, with and without Treg depletion. (C) Frequencies of CD4 T cells in 608 
the lung (top panel) and BAL (bottom panel) quantified by flow cytometry on day 2 609 
and 4 post RSV infection. Graphs show data from one representative out of three 610 
independent experiments with 5 mice per group in each case. Results are presented 611 
as means ± SEM. The significance of results between the groups was analyzed by 612 
two-tailed, unpaired Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001. 613 
  614 
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Supplemental Figure S3. Tregs in the lung express CCR4. 615 
 616 
FI-Mock or FI-RSV vaccinated mice were infected with RSV on day 0 and 617 
lymphocytes recovered by BAL on day 4. When indicated mice were injected with IL-618 
2 Cx on days -3, -2 and -1. (A) Expression of CCR4 on Tregs and CD4 T cells in the 619 
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BAL measured by flow cytometry on day 4 post infection. (B) Quantification of CCR4 620 
expression on Tregs and CD4 T cells in the BAL on days 2 and 4 post infection 621 
measured as mean fluorescent intensity (MFI). (C) Relative expression of CCR4 to 622 
GAPDH of BAL CD4 T cells and Tregs on day 4 post infection determined by real-623 
time PCR of FI-RSV vaccinated and RSV infected mice. PCR was performed on 624 
pooled FACS sorted cells. (D) Relative expression of CCR4 to GAPDH of CD4 T 625 
cells and Tregs in the lung on day 2 and day 4 post infection determined by real-time 626 
PCR of pooled FACS sorted cells. (E) Levels of chemokines CCL17 and CCL22 in 627 
the BAL of FI-RSV vaccinated mice measured by ELISA on day 2 and 4 post RSV 628 
infection. Data is pooled from two independent experiments, 4-5 mice per group in 629 
each graph. Results are presented as means ± SEM. The significance of results 630 
between the groups was analyzed by two-tailed, unpaired Student’s t test. *p < 0.05, 631 
**p < 0.01, ***p < 0.001. 632 
  633 
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Supplemental Figure S4. Effects of instillation of CCL17 and/or CCL22 in the 634 
airways of FI-RSV vaccinated mice after RSV infection. 635 
636 
  637 
38 
 
(A) Quantification of frequencies of Tregs and CD4 T cells on day 2 and 4 post RSV 638 
infection in FI-RSV vaccinated and either CCL17 or CCL22 treated mice. (B) 639 
Frequencies of CD4+IFN-γ+ T cells, CD4+TNF-α+ T cells and CD4+TNF-α+IFN-γ+ T 640 
cells in the BAL on day 4 post RSV infection were quantified using flow cytometry on 641 
day 2 and 4 post RSV infection. (C) Frequencies (right) and total numbers (left) of 642 
macrophages, neutrophils (PMNS) and eosinophils in the BAL were quantified using 643 
differential cell counting of H&E stained cytospins slides on day 4 post infection. 644 
Graphs show data from one representative out of two independent experiments with 645 
5 mice per group in each case. Results are presented as means ± SEM. The 646 
significance of results between the groups was analyzed by two-tailed, unpaired 647 
Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001. 648 
  649 
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Supplemental Figure S5. Late effects of chemoattraction of Tregs into the 650 
airways by CCL17/22. 651 
 652 
40 
 
BALB/c mice were vaccinated with FI-RSV and infected three weeks later with RSV 653 
i.n. (day 0). When indicated, mice were treated i.n. with a mixture of 0.5 µg of both 654 
CCL17 and 22, or PBS on day 2 post RSV infection. (A) Frequencies of Tregs in the 655 
BAL were quantified using flow cytometry on day 8 post RSV infection with (‘17/22’) 656 
or without (‘nil’) intranasal administration of CCL17/22. (B) Quantification of Tregs 657 
and CD4 T cells frequencies in the BAL on day 8 post RSV infection. (C) 658 
Quantification of total numbers of Tregs and CD4 T cells in the BAL on day 8 post 659 
RSV infection. Graphs show data from one representative out of two independent 660 
experiments with 5 mice per group in each case. Results are presented as means ± 661 
SEM. The significance of results between the groups was analyzed by two-tailed, 662 
unpaired Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001. 663 
  664 
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Supplemental Figure S6. Anti-CCL17/22 treatment decreases Treg frequencies. 665 
 666 
Mice were injected i.p. with anti-CCL17 and 22 antibodies or goat IgG control on day 667 
1 post RSV infection into FI-RSV vaccinated mice prior to instillation of CCL17/22 on 668 
day 2 post infection. Quantification of Tregs (left) and CD4 T cells (right) frequencies 669 
in the BAL on day 4 post RSV infection. Graphs show data from one representative 670 
out of two independent experiments with 5 mice per group in each case. Results are 671 
presented as means ± SEM. The significance of results between the groups was 672 
analyzed by two-tailed, unpaired Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001. 673 
  674 
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Supplemental Figure S7. The balance of regulatory and disease-causing T 675 
cells in RSV infection. 676 
677 
 (A) The airways of clean mice contain alveolar macrophages but no other immune 678 
cells. (B) In RSV primary infection, macrophages become activated and CD4 and 679 
CD8 T cells migrate into the lung and airways. These are kept in check by Tregs, 680 
which require granzyme B to function (20); both CD4 and CD8 T cells produce IL-10, 681 
which assists in modulation of the immune response (31). (C) RSV infection of mice 682 
previously vaccinated with FI-RSV show a rapid and exuberant CD4 T cell response, 683 
leading to mediator release into the local environment and shut-down of the 684 
production of CCL17/22 by resident cells. These chemokines normally recruit Tregs 685 
into the airways, so a decline in chemoattraction of Treg enhances disease. (D) 686 
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Administration of CCL17/22 intranasally bypasses the shut-down of Treg recruitment 687 
and attenuates vaccine-augmented disease, reducing disease severity. 688 
 689 
